Micafungin Shortage Update: What Patients Need to Know in 2026

If you are a patient receiving micafungin (brand name Mycamine) for a serious fungal infection, staying informed about the medication's availability is critical to your care. Drug shortages in the specialty injectable medication space can occur with little warning, and micafungin falls into a category of medications that has historically been vulnerable to supply disruptions. Here is what you need to know about the micafungin supply situation in 2026.

Is Micafungin in Shortage in 2026?

As of early 2026, micafungin is not listed on the FDA Drug Shortages Database as an active shortage. This is positive news for patients who depend on it. Generic micafungin for injection is manufactured by multiple companies, which provides a more resilient supply chain compared to single-source specialty drugs.

However, patients and caregivers should be aware that the absence of a formal FDA shortage does not mean micafungin is universally easy to access. Access challenges can still occur at the specialty pharmacy level, particularly for home infusion patients who are transitioning out of the hospital.

Historical Shortage Context

Micafungin, like many sterile injectable antifungals, has faced supply pressures over the years. Sterile injectables are among the most shortage-prone categories of drugs in the United States due to complex manufacturing requirements, limited production capacity at specialized facilities, global raw material dependencies, and thin profit margins that reduce manufacturer investment. Between 2022 and 2024, the average selling price of micafungin decreased by over 15%, reflecting competitive generic pressure that, while benefiting costs, can also reduce financial incentives for manufacturers to maintain robust production capacity.

What Factors Could Cause a Micafungin Shortage?

Even when there is no current shortage, patients benefit from understanding the risk factors. Factors that could trigger a future micafungin shortage include:

Manufacturing quality issues: Sterile injectable production requires extremely high quality controls. FDA inspections that identify deficiencies can halt production.

Raw material shortages: Key pharmaceutical ingredients are often sourced from India and China. Global supply chain disruptions can interrupt production.

Demand surges: Rising rates of immunocompromised patients from cancer treatment, organ transplantation, and HIV/AIDS drive increasing demand for antifungal agents.

Manufacturer consolidation: If one or more generic manufacturers exit the market, remaining suppliers may struggle to meet total demand.

What Should Patients Do Now?

Even in a period of good availability, there are steps patients and caregivers can take to protect themselves against access disruptions:

Do not delay treatment planning. If you know you will need a prolonged course of IV micafungin (for example, 14 days or more for candidemia), confirm availability with your infusion pharmacy well in advance.

Ask your care team about their shortage protocol. Hospitals maintain shortage management plans and can often substitute caspofungin or anidulafungin if micafungin becomes unavailable.

Keep a record of your current treatment course. Document the manufacturer, lot number, vial strength, and dosing schedule. This information can be helpful if your pharmacy needs to transition to a different supplier.

Use medfinder if you encounter access problems. Visit medfinder.com to search for pharmacies with micafungin in stock near you.

How to Tell If Your Pharmacy Is Having Supply Issues

Signs that your pharmacy may be experiencing a supply issue include: being told the drug is on back order, being offered a substitute without explanation, receiving a smaller-than-expected supply, or experiencing an unexpected delay in delivery. If any of these occur, ask your pharmacist directly: Is micafungin on back order? When do you expect new stock? Can you refer me to another pharmacy that has it in stock?

How FDA Monitors and Responds to Shortages

The FDA requires manufacturers to notify the agency when they anticipate supply disruptions that could lead to shortages. The FDA Drug Shortage Staff works with manufacturers to address production issues, expedite inspections, and in some cases approve temporary importation of foreign versions of drugs to maintain supply. Patients can monitor the FDA Drug Shortage Database (fda.gov/drugs/drug-shortages) to check current status for micafungin and other medications.

Current Supply Outlook for 2026

The micafungin market is currently served by multiple generic manufacturers, providing a more resilient supply base than single-source drugs. The global echinocandin market is projected to grow through 2032, driven by increasing rates of invasive fungal infections in immunocompromised populations. This demand growth supports continued manufacturer investment in production capacity. Overall, the supply outlook for micafungin in 2026 is reasonably stable, with no active FDA shortage as of the time of writing.

If you are encountering access problems, read our guide on alternatives to micafungin when you cannot fill your prescription for clinical options to discuss with your doctor.